AbbVie vs. Pfizer: Which Dividend Stock Is the Better Buy in September?
AbbVie vs. Pfizer: Which Dividend Stock Is the Better Buy in September? The Motley Fool
Covered in this story
What has happened since
- AbbVie is up 0.8% since this was published, 6 days ago.
- Pfizer is up 3.1% since this was published, 6 days ago.
Price move measured from the close nearest publication to the latest quote.
Call it yourself
No calls on $ABBV yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on AbbVie →Also covered by 1 other outlet
Dalsna Finance is currently tracking 52 stories mentioning AbbVie, the earliest published 19 Mar 2026.
Summary aggregated from The Motley Fool's public RSS feed. The full reporting belongs to The Motley Fool — please read it on their site.